Kura Oncology (KURA) Cash & Equivalents (2010 - 2026)

Kura Oncology (KURA) has 17 years of Cash & Equivalents data on file, last reported at $39.1 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $39.1 million, down 23.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.1 million (down 23.77% YoY), and the FY2025 annual result was $149.1 million, down 33.57% from the prior year.
• Cash & Equivalents retreated to $39.1 million in Q1 2026 per KURA's latest filing, from $149.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $224.5 million in Q4 2024 and troughed at $27.1 million in Q1 2023.
• A 5-year average of $66.8 million and a median of $49.1 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents slumped 69.48% in 2022, then jumped 501.48% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $51.8 million in 2022, then fell by 27.96% to $37.3 million in 2023, then jumped by 501.48% to $224.5 million in 2024, then tumbled by 33.57% to $149.1 million in 2025, then plunged by 73.79% to $39.1 million in 2026.
• Business Quant data shows KURA's Cash & Equivalents at $39.1 million in Q1 2026, $149.1 million in Q4 2025, and $95.3 million in Q3 2025.